Restoration of Foxp3 + Regulatory T-cell Subsets and Foxp3-Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases during Anti-tumor Necrosis Factor Therapy

Abstract

Background: A defect in regulatory T cells (Tregs) may be involved in the pathogenesis of inflammatory bowel diseases (IBD). Several subsets of human Foxp3 + Tregs (activated and resting Tregs) have now been identified, as well as an IL-10 and IFN-γ double producing Foxp3-type 1 regulatory-like T cell (Tr1L). We have quantified these Tregs in patients with active IBD and during therapy with infliximab (IFX). Methods: Blood samples were obtained from healthy controls (n 54) and patients with active IBD, either before (n 62) or during IFX therapy (n 75). Tregs were identified by immunofluorescent staining and flow cytometry analysis. Resting and activated Foxp3 + Tregs can be differentiated from Foxp3 + effector T cells (Foxp3 + Teff) by the expression of CD45RA. Tr1L are identified as CD4 + CD45RA-CD25-CD127-Foxp3-T cells. Results: A numerical deficiency of circulating resting Tregs, activated Treg cells, and Tr1L was documented in patients with active IBD. Baseline levels of these Treg subsets predicted clinical responses to IFX. We documented an upregulation of all 3 subsets during IFX therapy. Moreover, after therapy, significant differences in Treg subsets were seen between responders and nonresponders to IFX. Restoration of Tregs correlated with the clinical and biological response to IFX therapy. Trough serum levels of IFX positively correlated with the proportion of activated Treg cells and Tr1L during therapy. Conclusions: IFX therapy, when successful, results in upmodulation of the different types of Treg cells in the blood of patients with IBD. This effect might be relevant for understanding the mechanism of action of anti-TNF agents.